SIGA Technologies Q3 net loss narrows on international sales
Overview
U.S. pharmaceutical firm's Q3 revenue and product sales declined year-over-year
Company posted Q3 net loss, narrowing from year-ago period
Awarded $15 mln oral TPOXX contract from Canadian Department of National Defence in October
Outlook
Company is actively pursuing new international government contracts to diversify its customer base
SIGA continues to seek a new TPOXX procurement contract with the U.S. Government
Canadian Department of National Defence contract includes firm commitments of about $9 mln over three years
Result Drivers
INTERNATIONAL SALES - Co delivered $13 mln of oral TPOXX to two international customers in first nine months
U.S. CONTRACT FULFILLMENT - Co completed final IV TPOXX deliveries to U.S. Strategic National Stockpile under 19C contract
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss | $2.9 mln |
Analyst Coverage
The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 5 three months ago
Reuters Recommended Reads
Nov 9 - Tonix Pharmaceuticals Q3 revenue jumps on TONMYA sales
Nov 9 - Ocular Therapeutix Q3 loss widens as product revenue drops, costs rise
Nov 9 - TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)